Search research articles
Contact Us
Filters
Showing results (21-30 of 129) with videos related to
Page
of 13
Sort By:
Expert Opinion on Pharmacotherapy
|
June 9, 2023
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy
Efrat Luttwak, Mitchell R Smith, Andrew D Zelenetz
Clinical Advances in Hematology & Oncology : H&O
|
March 11, 2009
Review: lymphomatoid granulomatosis: challenges in diagnosis and treatment
Elena Gitelson, Tahseen Al-Saleem, Mitchell R Smith
Discoveries (Craiova, Romania)
|
August 18, 2015
New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals
Andreea Lucia Stancu, Mitchell R Smith, Alexandru Almasan
European Journal of Pharmacology
|
October 20, 2009
Immunotherapy of cancer
Hossein Borghaei, Mitchell R Smith, Kerry S Campbell
Stem Cells and Cloning : Advances and Applications
|
November 8, 2013
Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
Satish Shanbhag, Mitchell R Smith, Robert Vb Emmons
Clinical Lymphoma, Myeloma & Leukemia
|
February 19, 2025
Follicular Lymphoma: Paving the Path to Cures Through Philanthropy
Mitchell R Smith, Michel Azoulay, Lee M Greenberger
Diagnostic Cytopathology
|
May 4, 2021
Crystal-storing histiocytes in ascites leading to a diagnosis of plasma cell myeloma
Fatima Hamadeh, Mitchell R Smith, Eric D Hsi
Academic Radiology
|
April 28, 2004
Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine
Fernando Arias-Mendoza, Mitchell R Smith, Truman R Brown
Medicine and Science in Sports and Exercise
|
December 11, 2014
Mental Fatigue Impairs Intermittent Running Performance
Mitchell R Smith, Samuele M Marcora, Aaron J Coutts
Leukemia & Lymphoma
|
April 11, 2014
Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin
Brian T Hill, Raymond R Tubbs, Mitchell R Smith
Page
of 13
Search research articles
Search
Showing results (21-30 of 129) with videos related to
Sort By:
Page
of 13
Expert Opinion on Pharmacotherapy
|
June 9, 2023
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy
Efrat Luttwak, Mitchell R Smith, Andrew D Zelenetz
Clinical Advances in Hematology & Oncology : H&O
|
March 11, 2009
Review: lymphomatoid granulomatosis: challenges in diagnosis and treatment
Elena Gitelson, Tahseen Al-Saleem, Mitchell R Smith
Discoveries (Craiova, Romania)
|
August 18, 2015
New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals
Andreea Lucia Stancu, Mitchell R Smith, Alexandru Almasan
European Journal of Pharmacology
|
October 20, 2009
Immunotherapy of cancer
Hossein Borghaei, Mitchell R Smith, Kerry S Campbell
Stem Cells and Cloning : Advances and Applications
|
November 8, 2013
Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
Satish Shanbhag, Mitchell R Smith, Robert Vb Emmons
Clinical Lymphoma, Myeloma & Leukemia
|
February 19, 2025
Follicular Lymphoma: Paving the Path to Cures Through Philanthropy
Mitchell R Smith, Michel Azoulay, Lee M Greenberger
Diagnostic Cytopathology
|
May 4, 2021
Crystal-storing histiocytes in ascites leading to a diagnosis of plasma cell myeloma
Fatima Hamadeh, Mitchell R Smith, Eric D Hsi
Academic Radiology
|
April 28, 2004
Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine
Fernando Arias-Mendoza, Mitchell R Smith, Truman R Brown
Medicine and Science in Sports and Exercise
|
December 11, 2014
Mental Fatigue Impairs Intermittent Running Performance
Mitchell R Smith, Samuele M Marcora, Aaron J Coutts
Leukemia & Lymphoma
|
April 11, 2014
Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin
Brian T Hill, Raymond R Tubbs, Mitchell R Smith
Page
of 13